Market Newsdesk

– Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events

• Stabilization of sleep apnea measures: The mean total Apnea-Hypopnea Index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group;
  i
  n children younger than 8 years of age, the mean total AHI was unchanged for the oral infigratinib group, versus a 63.2% increase in the placebo group

• Reduction in rate of ear infections: The estimated annualized rate of otitis media events was 38% lower in the oral infigratinib group compared to the placebo group; in children younger than 8 years of age, the annualized rate of otitis media events was 47% lower in the oral infigratinib group compared to the placebo group
  

–
In children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained improvements in growth (CFBL in height Z-score of +0.92 SD at Year 3) and body proportionality (CFBL in upper-to-lower body segment ratio of -0.15 at Year 3), with a well-tolerated safety profile and no new safety signals

– These findings build on the previously reported PROPEL 3 primary and secondary endpoint results published in NEJM, in which oral infigratinib demonstrated a +2.10 cm/year improvement in AHV versus placebo (p<0.0001) and a statistically significant improvement in body proportionality within 52 weeks in children younger than 8 years of age

– BridgeBio submitted an NDA to the FDA for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027 

PALO ALTO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today presented new exploratory analyses from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, showing directionally favorable trends beyond growth across medical complications associated with achondroplasia, including sleep apnea, otitis media, and body composition. These data were presented at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, in a late-breaking oral presentation by Julie Hoover-Fong, M.D., Ph.D. of Johns Hopkins University, U.S.

“In the past, achondroplasia research has focused largely on measuring growth because height can be readily determined. But families have consistently emphasized that their priorities extend well beyond the growth chart,” said Melita Irving, M.D. of Guy’s and St Thomas’ NHS Foundation Trust, London, UK. “Growth is only one part of the picture of this medically complicated condition in which children experience disrupted sleep, recurring ear infections, or other health challenges associated with achondroplasia. What I find especially encouraging here is not only the consistent benefit observed across each measure, but that the longer-term data from the PROPEL program show improvements in growth and body proportionality sustained through three years of treatment, and a safety profile that remained favorable with no new safety signals identified. Taken together, these findings suggest there is potential to address a broader range of outcomes that may meaningfully affect a child’s health and daily life over time.”

The new exploratory results from PROPEL 3 shared at ESPE 2026 include:

• Stabilization of sleep apnea measures:
  • The mean total apnea-hypopnea index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group
  • In children younger than 8 years of age, the mean total AHI at 52 weeks was unchanged for the oral infigratinib group, versus a 63.2% increase for the placebo group
• Reduction in rate of ear infections: The estimated annualized rate of otitis media, a recurrent complication in children with achondroplasia that can affect hearing and speech development, was 38% lower in the oral infigratinib group compared to the placebo group, and in children younger than 8 years of age, 47% lower in the oral infigratinib group compared to the placebo group
• Impact on body composition: Mean change from baseline in body mass index was smaller in the oral infigratinib group compared to placebo (0.50 versus 0.93 kg/m²), with a greater increase in lean body mass (1.77 versus 1.58 kg) and smaller increases in body fat mass (0.95 versus 1.12 kg) and visceral fat volume (1.55 versus 18.42 mL) compared to placebo

In addition to the late-breaking oral presentation at the Annual ESPE Meeting 2026, BridgeBio shared a poster, Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia, presented by Dr. Irving. These findings showed that in children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained improvements in growth, with a change from baseline in height Z-score relative to the achondroplasia population of +0.92 SD at Year 3. Additionally, oral infigratinib demonstrated sustained improvements in proportionality, with a change from baseline in upper-to-lower body segment ratio of -0.15 at Year 3. Results showed that oral infigratinib continued to be well-tolerated, with no new safety signals identified.

BridgeBio also shared one poster focused on PROPEL Infant & Toddler (I&T), an ongoing Phase 2/2b study in children under 3 years old with achondroplasia and one eposter focused on qualitative research on the impacts of hypochondroplasia.

PROPEL 3 demonstrated best-in-class improvements in annualized height velocity (AHV) and, for the first time in a Phase 3 achondroplasia study, statistically significant improvements in body proportionality and arm span, supporting its potential as the first oral targeted therapeutic option that directly impacts FGFR3. The topline results can be found here. These data were published as an original research article in the New England Journal of Medicine (NEJM) and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation. The results can be found here. 

BridgeBio believes oral infigratinib is positioned to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia. The Company submitted an NDA to the FDA for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027. The Company intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026. 

Oral infigratinib has received Breakthrough Therapy Designation from the U.S. FDA based on the shared results from the PROPEL 2 clinical trial, which meet the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. In addition to receipt of Breakthrough Therapy Designation, oral infigratinib has also received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA. If oral infigratinib is approved, BridgeBio may qualify for a Priority Review Voucher. 

Information about PROPEL I&T trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions, which hold significant unmet needs for families. 

About Achondroplasia 
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia can be associated with medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis, which may impact overall health and wellbeing. The condition is uniformly caused by an activating variant in FGFR3. 

About Oral Infigratinib 
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3.

About BridgeBio 
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok. 

BridgeBio Forward-Looking Statements 
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data regarding oral infigratinib, including the potential for oral infigratinib to provide benefits beyond growth and to meaningfully affect a broader range of medical and functional outcomes associated with achondroplasia; the potential for oral infigratinib to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia; the potential regulatory approval and commercialization of oral infigratinib, including BridgeBio’s anticipated U.S. launch in mid-2027; BridgeBio’s plans to submit a Marketing Authorization Application for oral infigratinib in achondroplasia to the European Medicines Agency in the second half of 2026; BridgeBio’s potential eligibility to receive a Priority Review Voucher if oral infigratinib is approved; and BridgeBio’s plans to continue exploring the potential of oral infigratinib to address broader medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data; the design, enrollment, conduct, timing and success of ongoing and planned clinical trials; the risk that results from exploratory endpoints, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects; that observed trends or improvements in medical or functional outcomes may not be replicated in additional analyses or studies or translate into meaningful long-term clinical benefits; that oral infigratinib may not demonstrate benefits beyond growth or achieve the anticipated clinical, regulatory or commercial profile; that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, or may require additional data, studies or other information; that BridgeBio may not launch oral infigratinib in the U.S. in mid-2027 or on the anticipated timeline; that BridgeBio’s planned regulatory submissions, including its planned MAA submission, may be delayed or may not occur as expected; that oral infigratinib may not become the first and only approved oral therapy or a best-in-class option for achondroplasia; that BridgeBio may not qualify for or receive a Priority Review Voucher; and that BridgeBio’s plans to study or develop oral infigratinib for broader medical and functional impacts or additional skeletal dysplasia conditions may change or may not result in successful development or regulatory approval; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact: 
Kaitlyn Reilly, Director, Communications
[email protected]
(650) 789-8220 

BridgeBio Investor Contact: 
Kristen Kelleher, Director, Investor Relations
[email protected]

New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) — Premium Catering (Holdings) Limited (NASDAQ: PC, or the “Company”), today announced that today announced that it has received a letter from the Nasdaq Stock Market, dated September 4, 2026 (the “Delinquency Letter”), notifying the Company that it is not in compliance with the requirements for continued listing set forth in NASDAQ Listing Rule 5250(c)(1) because it did not timely file its interim report on Form 6-K containing an interim balance sheet and income statement for its fiscal half year ended December 31, 2025 (the “2026 Interim Report”), it no longer complies with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires that listed companies timely file all required periodic financial reports with the Securities and Exchange Commission. In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Delinquency Letter to submit a plan to regain compliance with the Rule (the “Compliance Plan”). If Nasdaq accepts the Compliance Plan, Nasdaq may grant the Company an extension until 180 calendar days from the date of the 2026 Interim Report’s due date, or December 28, 2026, to regain compliance. The Company intends to submit the Compliance Plan within the prescribed 60-day period.

The Delinquency Letter has no immediate impact on the listing of the Company’s Class A ordinary shares on the Nasdaq Capital Market, which will continue trading under the symbol “PC”. However, if the Company fails to regain compliance with the Rule, the Company’s Class A ordinary shares will be subject to delisting from the NASDAQ.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About Premium Catering (Holdings) Limited

Premium Catering (Holdings) Limited is a Singapore-based, certified Halal food caterer founded in 2012 that primarily supplies budget-prepared meals to foreign workers in dormitories, construction, marine, and manufacturing industries.

Core Business Operations

• Budget Prepared Meals: Supplies high-volume, 7-day-cycle menu meals tailored to specific cultural and religious dietary needs, featuring Indian (vegetarian and non-vegetarian), Bangladeshi, and Chinese cuisines.
• Smart Incubators: Utilizes custom-made compartmentalized, heated, and insulated food dispensing units introduced since 2019 for easy meal collection.
• Buffet & Event Catering: Provides full buffet services for private functions, corporate gatherings, and community events.
• Dormitory Food Stalls: Operates on-site food stalls and offers ancillary bulk-order delivery services.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, the Company’s submission of a Compliance Plan, the Company’s ability to regain compliance with Nasdaq Listing Rules, the continued listing of the Company’s securities on the Nasdaq, and whether or not Nasdaq accepts any Compliance Plan.. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 20-F for the year ended June 30, 2025 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:

Premium Catering (Holdings) Limited
Ka Hei Wong, Chief Financial Officer
[email protected]

SAN JOSE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, today announced Zscaler Agentic SOC, a new approach to security operations built to proactively reduce exposures, scale human expertise and stop AI-driven attacks at machine speed. In today’s threat landscape, simply layering in AI capabilities onto the existing security stack will not provide the protection needed. Zscaler is delivering a new solution to the security operations center (SOC), purpose-built from the ground up with an AI-first approach to detect, investigate, and stop threats at machine speed.

Today’s threat landscape is defined by speed and stealth as AI-driven attacks move faster than SOC teams can manually correlate, analyze, and remediate. Threatlabz, Zscaler’s global research team, is also seeing a rise in evasive tactics, including the use of trusted sites to host attacks, abuse of legitimate remote management tools, and browser-based attacks. Zscaler Agentic SOC is built to meet that challenge by combining unique Zscaler telemetry, the world’s largest decoy mesh network, expert-validated agents, integrated Zscaler Zero Trust controls, and customers’ third-party controls to detect threats earlier and automate containment at machine speed.

To power Agentic SOC, Zscaler has partnered with leading frontier AI labs, including Anthropic and OpenAI. By integrating their frontier models alongside Zscaler’s proprietary threat intelligence and zero trust telemetry, Zscaler is able to deliver AI agents that reason with greater depth, accuracy, and explainability than any single model or approach could achieve alone. This extends beyond threat detection, with Zscaler’s open platform approach enabling direct integration with frontier models, allowing security teams to ingest vulnerability findings and operationalize them within their SOC workflows. This collaboration reflects Zscaler’s commitment to building on the best available AI that includes speed, reliability and transparency that security operations demand.

“AI-driven attacks are moving faster than traditional SOC models were ever designed to handle,” said Deepen Desai, Executive Vice President of Cybersecurity at Zscaler. “Agentic SOC is a fundamental rethinking of security operations, built with agentic capabilities at its core to reduce exposures proactively, extend human expertise with AI agents and contain threats at machine speed. With unmatched inline telemetry, specialized AI agents and closed-loop remediation, Zscaler is giving security teams the visibility and control they need to outpace modern attackers.”

“The past year has made one thing clear: AI attacks are fundamentally changing the threat landscape, operating at a speed, scale, and level of adaptability that looks very different from traditional human-led activity,” said Allie Mellen, principal analyst and author of Code War: How Nations Hack, Spy, and Shape the Digital Battlefield. “To defend effectively, organizations must double down on the fundamentals — Zero Trust principles, preventing data exfiltration, limiting access, and making AI attacks as expensive as possible.”

Reimagining SecOps: The Zscaler Differentiation

• Unified exposure and threat management: Zscaler connects proactive attack surface reduction with reactive threat defense in a single platform, enriching context and accelerating protection.
• Unmatched zero trust telemetry: Zscaler sits inline, capturing network, identity, endpoint, cloud and AI insights across its 750 billion daily zero trust transactions that security teams can operationalize for real-time detection and response.
• Specialized AI agents built on frontline experience: Zscaler AI agents have been trained and continuously tuned on more than 10 years of frontline SOC, managed detection and response and threat-hunting experience, informed by threat intelligence derived from thousands of customer environments globally.
• Closed-loop inline remediation: Zscaler automatically contains threats at machine speed with native inline controls that can isolate compromised users, block command-and-control communications, and cut off lateral movement. Integrations with customers’ third-party tooling provide increased options for nuanced responses to active threats.

“Our team was drowning in alert noise, forcing top analysts into triage instead of proactive threat hunting,” said Andrea Liccardi, Sr. Cybersecurity Manager, Maire Tecnimont. “Zscaler Agentic SOC gives us full attack-path context using telemetry we already had in place, helping our team move from fragmented signals to faster, more informed decisions. Zscaler has proven to be one of our most valuable cybersecurity partners, continuously helping us improve operational efficiency, visibility, and our ability to focus our analysts on what really matters.”

Open Platform Integration

Zscaler Agentic SOC seamlessly integrates with your existing security ecosystem, pulling in third-party data to contextualize risks and threats. By triggering automated outbound actions, it proactively eliminates exposures and contains attacks at machine speed.

Key Features of Zscaler Agentic SOC

• Data-rich context graph: Correlates real-time zero trust telemetry with third-party data to map, prioritize and investigate complex incident chains.
• Specialized AI agents: Autonomous agents perform dedicated roles across triage, root-cause investigation, assigning verdicts, and triggering response workflows, reducing analyst workload and accelerating defenses.
• Advanced detections informed by threat intelligence: Applies frontline threat research and rich telemetry to identify sophisticated attacks earlier and with greater precision.
• Continuous threat hunting and expert support: Combines AI speed with seasoned human judgment from Zscaler and Red Canary security experts.

Availability and Additional Information

Zscaler Agentic SOC is available globally today. To learn more, register for the global launch webinar or visit zscaler.com/solutions/agentic-secops.

Follow Zscaler on LinkedIn, X, and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include the expected adoption, performance and benefits of Zscaler Agentic SOC, including its AI agents, third-party integrations and automated threat-containment and remediation capabilities. These forward-looking statements are subject to the safe harbor provisions created by the Private Securities Litigation Reform Act of 1995. A significant number of factors could cause actual results to differ materially from statements made in this press release, including those factors related to Zscaler’s ability to deliver and achieve customer adoption of Zscaler Agentic SOC and the performance and effectiveness of its AI-driven and automated capabilities. Additional risks and uncertainties are set forth in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on September 3, 2026, which is available on our website at ir.zscaler.com and on the SEC’s website at www.sec.gov. Any forward-looking statements in this release are based on the limited information currently available to Zscaler as of the date hereof, which is subject to change, and Zscaler will not necessarily update the information, even if new information becomes available in the future.

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange™ platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across over 200 public data centers globally and thousands of private sites at the edge, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Media Contact

Nick Gonzalez, Director, Public Relations, [email protected]

LONDON, Sept. 09, 2026 (GLOBE NEWSWIRE) — StoneX Group Inc. (NASDAQ: SNEX) today announced that City Index, one of UK’s most established trading brands, is relaunching as StoneX Trading.

The move to bring the self-directed business under the StoneX brand will provide retail traders with invaluable access to insights and market intelligence previously only available to institutional investors. The relaunch will also connect clients with the strength, scale and global expertise of the Fortune 50 financial services company, which has more than 80 offices worldwide.

The new StoneX Trading website is now live with the updated branding and experience introduced across digital channels, mobile applications and client communications.

Clients can continue trading as normal throughout the transition, with no changes to their platforms, accounts or support services. As City Index and StoneX Trading come together, clients will continue to enjoy the trusted trading experience they are already familiar with. The City Index UK brand will retire on 12 September, with all new account openings moving to StoneX Trading.

The move further aligns the retail business with StoneX’s broader global financial services franchise, which serves commercial, institutional, payments and self-directed clients.

Giles Watts, Regional Business Director, EMEA – Self Directed, StoneX, said:

“For decades, City Index has earned the trust of traders by delivering reliable platforms, broad market access and high-quality client services. Moving to StoneX Trading marks an exciting new chapter that builds on that legacy while bringing our retail offering under a brand recognised globally for its strength in financial markets.”

“For our clients, the transition is deliberately straightforward. They will continue using the same platforms and be serviced by the same support teams they know and trust today. The real change is in the brand behind the experience that reflects the additional scale, expertise and global capabilities of StoneX, which positions us to continue investing in the products, technology and services our clients value most.”

Alastair Hine, Global Head of Self Directed, StoneX, added:

“StoneX Trading represents our ambition for the future of self-directed trading. By bringing City Index’s trusted legacy together with the strength and global capabilities of StoneX, we are creating a much stronger platform for innovation and continued investment in the products, technology and overall experience offered to our clients.”

For further information, please visit the new StoneX Trading website at www.stonex.com/en-gb/individuals

About StoneX Group Inc.

StoneX Group Inc., through its subsidiaries, operates a global financial services network that connects companies, organisations, traders, and investors to the global market ecosystem through a unique blend of digital platforms, end-to-end clearing and execution services, high-touch service, and deep expertise. The company strives to be its clients’ trusted partner, providing its network, products, and services to help them pursue business opportunities, manage market risks, make informed investment decisions, and improve their business performance. 

A Fortune 50 company headquartered in New York City and listed on the Nasdaq Global Select Market (NASDAQ: SNEX), StoneX Group Inc. and its more than 5,400+ employees serve over 80,000+ commercial, institutional, and payments clients, as well as more than 260,000 retail accounts, across more than 80 offices on six continents. Further information is available at www.stonex.com/en-gb/ 

Media enquiries:

Marion Rannard
[email protected]

SNEX-G

Member FINRA/SIPC

KOBE, Japan, Sept. 09, 2026 (GLOBE NEWSWIRE) — Micware Co., Ltd. (Nasdaq: MWC) (the “Company” or “Micware”), a Japan-based provider of software development services and innovative IT solutions mainly focused on the automotive and mobility sectors, today announced the signing of a Memorandum of Understanding (“MOU”) with MulticoreWare, Inc. (“MultiCoreWare”) to explore potential collaboration on next-generation artificial intelligence (“AI”) solutions, with a focus on advanced driver assistance systems (“ADAS”) performance optimization and integration, AI-powered in-vehicle user experience, and physical AI at the edge.

Market Environment and Shared Understanding

The two companies share the view that edge and high-performance AI will serve as important foundations for the future of automotive, security and robotics.

As the industry shifts toward software-defined vehicles (“SDVs”) and autonomous physical AI systems, the need to perform AI inference locally and in real time continues to grow. This is because running AI solely in the cloud may not always be suitable for mission-critical applications that require deterministic execution, strict security and real-time control.

The companies aim to contribute to enhanced user experience and vehicle safety by advancing the implementation of Vision-Language-Action (“VLA”) models and large language models (“LLMs”) on cost- and power-efficient electronic control units (“ECUs”).

Background

Micware develops and provides software systems and IT solutions, with automotive and mobility-related systems, including in-vehicle infotainment, navigation, human-machine interface, telematics, driver assistance, and location-based services, as key areas of its business.

MulticoreWare is a software engineering and technology company headquartered in San Jose, California, with global operations in the U.S., Europe, India and China. The company has strengths in software development based on the architectures of heterogeneous System on a Chip (“SoC”) platforms.

The parties have entered into the MOU to explore potential collaboration, beginning with Japan, by combining Micware’s customer relationships, sales capability and experience in automotive software with MulticoreWare’s engineering capabilities in ADAS and AI.

Figure: Micware’s growth strategy centered on micAuto-PF and DynaPlanet-PF, including the expansion of its capabilities in the ADAS domain

Complementary Strengths

MulticoreWare: optimization across heterogeneous hardware

MulticoreWare has extensive experience in software engineering and optimization for heterogeneous SoC platforms. Its capabilities in ADAS integration and optimization, advanced 3D LiDAR sensing, and in-cabin radar and camera sensor fusion form the ECU-agnostic technical foundation of this collaboration.

Figure: MulticoreWare’s core technical capabilities and their relevance to the potential collaboration with Micware in ADAS, edge AI, and physical AI solutions.

Micware: automotive software and original equipment manufacturer (“OEM”) customer base

Since its founding in Kobe in 2003, Micware has built long-term relationships with major Japanese automotive manufacturers, including Honda Motor Co., Ltd. and Toyota Motor Corporation.

Micware’s in-vehicle software platform, micAuto-PF, is a modular in-vehicle infotainment (“IVI”) platform that supports Android- and Linux-based environments and is designed to enable the reuse of software components, such as navigation engines, multimedia functions and connectivity protocols, across multiple projects.

Micware’s growth strategy is to evolve from a Tier 1 software supplier in the IVI domain into a Tier 1 software supplier in the SDV domain. As part of this strategy, Micware aims to expand into ADAS and autonomous driving (“AD”) by leveraging the foundation it has developed in IVI, and to realize integrated solutions spanning from the cockpit to driving-control systems. This MOU is an initiative aligned with that direction.

Scope of the MOU

Under the MOU, the parties expect to discuss and explore potential areas of collaboration, including those set out below.

Area of Exploration	Description
Technical cooperation	Explore potential technology and engineering cooperation, including joint proof-of-concept (“PoC”) initiatives for the performance evaluation, integration and optimization of LLMs, VLA models and AI models optimized for ADAS and in-vehicle user experience.
Physical AI integration	Explore the potential to bridge hardware performance and complex software requirements, and to implement machine learning solutions on power-efficient edge devices.
Business development opportunities	Beginning in Japan, the parties expect to conduct joint customer interviews, identify customer challenges, develop joint proposals and explore potential projects by leveraging Micware’s relationships with automotive manufacturers and MulticoreWare’s engineering capabilities.
Customer value creation	Explore the potential to create customer value, including through joint proposals that may contribute to performance improvements and greater development efficiency in ADAS and automotive AI development.
Joint promotion / marketing activities	Explore potential joint promotional and marketing activities.

Nature of the MOU and Next Steps 

The MOU records the parties’ current mutual understanding regarding the commencement of discussions on potential collaboration. It does not obligate either party to enter into any agreement or to proceed with any particular collaboration activity. 

Should the parties pursue specific collaboration activities, they intend to enter into one or more separate agreements by mutual agreement. As of the date of this release, no definitive business arrangement regarding joint development, commercialization or product deployment has been concluded. 

The MOU remains in effect from its effective date until June 8, 2027, unless earlier terminated by either party upon written notice to the other. 

Management Commentary 

Kenji Narushima, Representative Director, President and Chairman, Micware Co., Ltd. 

“We believe that edge and high-performance AI are the foundations supporting next-generation innovation in automotive, security and robotics. By combining Micware’s strategic ecosystem, including our recent security alliance, with MulticoreWare’s capability to optimize AI across diverse hardware architectures, we expect to work toward the implementation of large-scale machine learning solutions that address evolving industry needs.” 

AGK Karunakaran, President & CEO, MulticoreWare 
“The next frontier of mobility and robotics depends heavily on highly optimized physical AI. By combining MulticoreWare’s core high-performance software expertise with Micware’s solid experience in the automotive industry, the two companies are positioned to provide superior solutions. Together, we will push the boundaries of ADAS algorithm performance and work toward enabling complex physical AI systems to operate safely and smoothly at the edge.” 

About Micware Co., Ltd. 

Micware Co., Ltd. is a Japan-based provider of software development services and innovative IT solutions mainly focused on the automotive and mobility sectors. The Company is primarily engaged in the development and sale of IVI systems covering multimedia, navigation, human machine interface, telematics, and driver assistance, as well as navigation software and location information-based smartphone applications. 

Since its founding in 2003, Micware has built over 20 years of experience in automotive software and has established long-term relationships with major OEMs in Japan, including Honda and Toyota. Leveraging its engineering capabilities, proprietary technologies, and long-standing OEM relationships, the Company was ranked 9th among Japan-based Tier 1 suppliers in the IVI market in terms of revenue as of February 28, 2024, according to an industry report titled “IVI, Automotive Navigation System and Digital Mapping Market” commissioned by the Company and prepared by Frost & Sullivan. Micware operates across Japan through six operating entities and 13 branch offices and has established subsidiaries in the United States, Thailand, and Germany for overseas operations. 

For more information, please visit the Company’s IR website: www.ir-micware.com. 

About MulticoreWare 

MulticoreWare, Inc. is a global technology company that provides AI software solutions and engineering services to accelerate innovation in physical AI, agentic AI, robotics, edge intelligence and accelerated computing. Leveraging its expertise in multimodal AI, VLA models, sensor perception and fusion, AI optimization, embedded systems and high-performance software, the company supports the transformation of advanced AI technologies into production-applicable solutions. Its technologies are used in automotive, robotics, industrial automation, smart cities, healthcare, defense and intelligent edge devices, and its video codec technologies support next-generation video experiences worldwide. 

For more information, visit www.multicorewareinc.com. 

Forward-Looking Statements 

This press release contains statements that may constitute “forward-looking statements” pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar expressions. 

These forward-looking statements are based on Micware’s views and assumptions as of the date of this press release and involve known and unknown risks, uncertainties and other factors. Actual performance, results or events may differ materially from those expressed or implied by these forward-looking statements. 

Although Micware believes that the expectations reflected in these forward-looking statements are reasonable, Micware does not provide any assurance that such expectations will be realized. Investors are cautioned not to place undue reliance on these forward-looking statements. 

All information in this press release is current as of its date, and Micware undertakes no obligation to update, revise or supplement any forward-looking statement, except as required under applicable law. 

For more information, please contact: 

Micware Co., Ltd. 
Investor Relations Department 

Phone: +81-3-6699-9899 
Email: [email protected] 

Public Relations 
Email: [email protected] 

Ascent Investor Relations LLC 
Tina Xiao 
Phone: +1-646-932-7242 
Email: [email protected] 

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/a5917d0c-e784-48b6-bc2d-29c3aad009a3

https://www.globenewswire.com/NewsRoom/AttachmentNg/0d12c44a-dc56-43bf-bb7e-18e24a550479